Document is current

Article History

Received: 24 January 2024

Accepted: 7 September 2024

First Online: 6 November 2024

Declarations

:

: This study was performed under an institutional animal care and use committee approved protocol at the University of Miami, with funding from Wallace H. Coulter Center for Translational Research at the University of Miami. Prasoon P Mohan, MD, Sapna Deo, PhD, Zhao-Jun Liu, PhD, Emre Dikici, PhD, Omaida C. Velazquez and Sylvia Daunert, PhD are co-inventors of the patent application below: Daunert S. Deo S, Velazquez O, Liu Z, Poozhikunnath Mohan P, Chang D, Dikici E. Stem cell Delivery System. U.S. Patent Application PCT/US2020/066413. Filed December 2019. Patent Pending. Dr. Omaida C. Velazquez and Dr. Zhao-Jun Liu are consultants to QuiAmbulat/Ambulerto Inc as Chief Medical Officer and Chief Scientific Officer, respectively, and in compliance with the policy for consultation at University of Miami (UM). QuiAmbulat/Ambulerto Inc is a regenerative cell and gene therapy spin-out from the University of Miami, developing new ways to treat vascular disease; it is owned and operated by Ventac Partners Inc; and it holds an exclusive License to UMIP-169 (intellectual property fully owned by University of Miami). Dr. Omaida C. Velazquez and Dr. Zhao-Jun Liu are co-inventors to UMIP-169 and co-founders of QUIAMBULAT LLC, a subsidiary of QuiAmbulat/Ambulerto Inc that is owned and operated by Ventac Partners Inc. The UM policy for inventors applies. Dr. Omaida C. Velazquez and Dr. Zhao-Jun Liu are funded by the NIH/NHLBI for research on various E-Selectin-derived vascular regeneration and wound healing technologies. All the work to-date is pre-clinical/experimental and no commercial products currently marketed. On behalf of all other authors, the corresponding author states that there are no other conflicts of interest related to this study.